These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34327795)

  • 1. Cutaneous lymphocytic vasculitis after administration of COVID-19 mRNA vaccine.
    Vassallo C; Boveri E; Brazzelli V; Rampino T; Bruno R; Bonometti A; Gregorini M
    Dermatol Ther; 2021 Sep; 34(5):e15076. PubMed ID: 34327795
    [No Abstract]   [Full Text] [Related]  

  • 2. SARS-CoV-2 vaccination-induced cutaneous vasculitis: Report of two new cases and literature review.
    Abdelmaksoud A; Wollina U; Temiz SA; Hasan A
    Dermatol Ther; 2022 Jun; 35(6):e15458. PubMed ID: 35306713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 vaccine-induced urticarial vasculitis.
    Dash S; Behera B; Sethy M; Mishra J; Garg S
    Dermatol Ther; 2021 Sep; 34(5):e15093. PubMed ID: 34369046
    [No Abstract]   [Full Text] [Related]  

  • 4. Possible case of mRNA COVID-19 vaccine-induced small-vessel vasculitis.
    Bostan E; Zaid F; Akdogan N; Gokoz O
    J Cosmet Dermatol; 2022 Jan; 21(1):51-53. PubMed ID: 34705320
    [No Abstract]   [Full Text] [Related]  

  • 5. A localised vasculitic-like skin rash following the second dose of COVID-19 vaccine.
    Abobaker A; Idris MA; Ogunjimi O
    Int J Infect Dis; 2022 Jan; 114():29-30. PubMed ID: 34742927
    [No Abstract]   [Full Text] [Related]  

  • 6. Cutaneous vasculitis due to COVID-19 vaccination.
    Gázquez Aguilera EM; Rodríguez García M; Cantón Yebra MT
    Med Clin (Barc); 2022 May; 158(10):493-494. PubMed ID: 34895746
    [No Abstract]   [Full Text] [Related]  

  • 7. Hypocomplementemic urticarial vasculitis case with hemophagocytic lymphohistiocytosis following SARS-CoV-2 mRNA vaccination.
    Iwamura N; Eguchi K; Koga T; Tsutsumi K; Araki T; Aramaki T; Takatani A; Terada K; Ueki Y
    Immunol Med; 2023 Jun; 46(2):97-107. PubMed ID: 36950829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extensive cutaneous leukocytoclastic vasculitis after Sinopharm vaccine: Case report and review of the literature.
    Azzazi Y; Abdelkader HA; Khedr H; El-Komy MHM
    J Cutan Pathol; 2022 Aug; 49(8):736-742. PubMed ID: 35355299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2.
    Visentini M; Gragnani L; Santini SA; Urraro T; Villa A; Monti M; Palladino A; Petraccia L; La Gualana F; Lorini S; Marri S; Madia F; Stefanini L; Basili S; Fiorilli M; Ferri C; Zignego AL; Casato M
    Ann Rheum Dis; 2022 Mar; 81(3):441-443. PubMed ID: 34819272
    [No Abstract]   [Full Text] [Related]  

  • 10. Cutaneous small-vessel vasculitis following COVID-19 vaccine.
    Kar BR; Singh BS; Mohapatra L; Agrawal I
    J Cosmet Dermatol; 2021 Nov; 20(11):3382-3383. PubMed ID: 34529877
    [No Abstract]   [Full Text] [Related]  

  • 11. Urticarial vasculitis triggered by SARS-CoV-2 vaccine (mRNA vaccine).
    Daldoul M; Korbi M; Bellalah A; Ben Fadhel N; Belhadjali H; Zili J
    J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):e743-e744. PubMed ID: 35604050
    [No Abstract]   [Full Text] [Related]  

  • 12. Pigmented purpuric dermatosis after BNT162B2 mRNA COVID-19 vaccine administration.
    Atak MF; Farabi B; Kalelioglu MB; Rao BK
    J Cosmet Dermatol; 2022 Feb; 21(2):435-437. PubMed ID: 34791786
    [No Abstract]   [Full Text] [Related]  

  • 13. Leukocytoclastic vasculitis as a cutaneous manifestation of ChAdOx1 nCoV-19 corona virus vaccine (recombinant).
    Sandhu S; Bhatnagar A; Kumar H; Dixit PK; Paliwal G; Suhag DK; Patil C; Mitra D
    Dermatol Ther; 2021 Nov; 34(6):e15141. PubMed ID: 34546608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous leukocytoclastic vasculitis after second dose of mRNA COVID-19 vaccine.
    Simon SC; Olsavszky V
    Dermatol Online J; 2022 Oct; 28(5):. PubMed ID: 36809133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous reaction to BNT162b2 mRNA COVID-19 vaccine.
    López-Valle A; Falkenhain-López D; Arranz CR
    Int J Dermatol; 2021 Jul; 60(7):891-892. PubMed ID: 33855706
    [No Abstract]   [Full Text] [Related]  

  • 16. Delayed cutaneous reactions after the administration of mRNA vaccines against COVID-19.
    Juárez Guerrero A; Domínguez Estirado A; Crespo Quirós J; Rojas-Pérez-Ezquerra P
    J Allergy Clin Immunol Pract; 2021 Oct; 9(10):3811-3813. PubMed ID: 34293500
    [No Abstract]   [Full Text] [Related]  

  • 17. Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura.
    Chanut M; Jaidi R; Kohn M; Grange T; Brones C; Lombion N; Rousselot P; Longval T
    Platelets; 2022 May; 33(4):652-653. PubMed ID: 35225144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological features of cutaneous reactions after mRNA-based COVID-19 vaccines.
    Tihy M; Menzinger S; André R; Laffitte E; Toutous-Trellu L; Kaya G
    J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):2456-2461. PubMed ID: 34459036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Localized cutaneous reaction to an mRNA COVID-19 vaccine.
    Edriss M; Farshchian M; Daveluy S
    J Cosmet Dermatol; 2021 Aug; 20(8):2380-2381. PubMed ID: 34129749
    [No Abstract]   [Full Text] [Related]  

  • 20. Intracerebral hemorrhage due to vasculitis following COVID-19 vaccination: a case report.
    Takeyama R; Fukuda K; Kouzaki Y; Koga T; Hayashi S; Ohtani H; Inoue T
    Acta Neurochir (Wien); 2022 Feb; 164(2):543-547. PubMed ID: 34783899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.